Cargando…

PTGES Expression Is Associated with Metabolic and Immune Reprogramming in Pancreatic Ductal Adenocarcinoma

Metabolic reprogramming is an established hallmark of multiple cancers, including pancreatic cancer. Dysregulated metabolism is utilized by cancer cells for tumor progression, metastasis, immune microenvironment remodeling, and therapeutic resistance. Prostaglandin metabolites have been shown to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murthy, Divya, Attri, Kuldeep S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138618/ https://www.ncbi.nlm.nih.gov/pubmed/37108468 http://dx.doi.org/10.3390/ijms24087304

Ejemplares similares

Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
por: Murthy, Divya, et al.
Publicado: (2018)

Effect of PTGES3 on the Prognosis and Immune Regulation in Lung Adenocarcinoma
por: Jiang, Wenyan, et al.
Publicado: (2023)

Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma
por: Murakami, Shigekazu, et al.
Publicado: (2016)

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming
por: Yang, Sen, et al.
Publicado: (2021)

Snail-Overexpression Induces Epithelial-mesenchymal Transition and Metabolic Reprogramming in Human Pancreatic Ductal Adenocarcinoma and Non-tumorigenic Ductal Cells
por: Liu, Menghan, et al.
Publicado: (2019)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma
por: Somerville, Tim D.D., et al.
Publicado: (2018)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Circular RNA expression in pancreatic ductal adenocarcinoma
por: Zhang, Qian, et al.
Publicado: (2019)

Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma
por: Wang, Han, et al.
Publicado: (2023)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

Association of Pancreatic Fatty Infiltration With Pancreatic Ductal Adenocarcinoma
por: Hori, Mika, et al.
Publicado: (2014)

Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
por: Pezzilli, Raffaele, et al.
Publicado: (2015)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
por: Zhang, Tianyi, et al.
Publicado: (2022)

Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma
por: Song, Hai-Yan, et al.
Publicado: (2018)

Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma
por: Gunda, Venugopal, et al.
Publicado: (2022)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma
por: Wilson, Gregory C., et al.
Publicado: (2023)

Identification of calcium and integrin-binding protein 1 as a reprogrammed glucose metabolism mediator to restrict immune cell infiltration in the stromal compartment of pancreatic ductal adenocarcinoma
por: Ma, Junrui, et al.
Publicado: (2023)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression
por: Cheung, Phyllis F., et al.
Publicado: (2022)

Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma
por: Murphy, N C, et al.
Publicado: (2008)

Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma
por: Liu, Zhao, et al.
Publicado: (2023)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)

Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
por: Gautam, Shailendra K., et al.
Publicado: (2023)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
por: Lau, Allison N, et al.
Publicado: (2020)

Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
por: Rai, Vikrant, et al.
Publicado: (2020)

Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma
por: Kudo, Yuzan, et al.
Publicado: (2019)

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
por: Espiau-Romera, Pilar, et al.
Publicado: (2020)

Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
por: Ali, Ahmad, et al.
Publicado: (2022)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
por: Hilmi, Marc, et al.
Publicado: (2018)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e448k8caq8vpe90fs2tjpnueph